As only about 11% of Americans have so far received the bivalent booster shots from Pfizer and Moderna, and only 30% of those over 65 years of age, the Biden ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

Rybelsus, Novo Nordisk’s GLP-1 also known as semaglutide, snagged a label update from the FDA, allowing patients to take it as a first-line treatment for Type II diabetes in 7 ...

B Capital, an investment firm co-founded by Eduardo Saverin of Facebook fame, has closed its inaugural healthcare fund. Add that to its capital growth fund, and B Capital says it ...

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and ...

A federal judge in West Virginia ruled in favor of AstraZeneca on Wednesday, adding six months of patent protection for its asthma and COPD inhaler blockbuster Symbicort. The latest ruling ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

The FDA recently added a new warning and precaution to the label of Horizon's blockbuster monoclonal antibody Tepezza (teprotumumab-trbw), which is used as a treatment for thyroid eye disease, to ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

Pfizer and Astellas are gunning to add a fourth indication to their cancer drug Xtandi with Phase III trial results released today. The study, looking at ...

LinusBio, a Mount Sinai spinoff starting out focused on neurological disorders like autism, announced Thursday it raised $16 million in Series A funding. Proceeds will go toward building its ...

Hand­ful of biotechs ex­pect­ed to IPO this fall, but many are stuck in ‘hold­ing pat­tern’ un­til 2024 ...